What is the pathophysiology of chronic heart failure and acute decompensated heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Heart Failure and Acute Decompensated Heart Failure

Core Pathophysiologic Mechanism

The fundamental pathophysiology of both chronic and acute heart failure centers on the myocardium's critical inability to maintain cardiac output sufficient to meet peripheral circulatory demands, triggering a vicious cycle of neurohormonal activation, hemodynamic deterioration, and progressive organ dysfunction. 1

The Vicious Cycle in Heart Failure

  • Myocardial dysfunction initiates a cascade where reduced cardiac output leads to decreased tissue oxygen delivery, triggering compensatory vasoconstriction that paradoxically increases systemic vascular resistance and further burdens the failing heart. 1, 2

  • This creates a self-perpetuating cycle: elevated systemic resistance increases left ventricular afterload, which worsens cardiac output, leading to more neurohormonal activation and progressive decompensation. 2

  • Left ventricular dysfunction specifically causes decreased blood pressure with impaired tissue oxygen delivery and neurohormonal activation, resulting in systemic venous congestion that affects kidneys, liver, lungs, and gut. 1

Structural and Cellular Mechanisms

Myocardial Injury Pathways

  • Myocyte stress from any cause (ischemia, pressure overload, volume overload) triggers inflammatory and immune responses that acutely and chronically impair contractile function. 1

  • Ischemic heart disease—now the dominant cause of adult heart failure (60-70% of cases)—initiates inadequate coronary blood flow that prevents the myocardium from meeting metabolic demands, causing direct loss of contractile function. 3, 4

  • Chronic remodeling involves altered cardiac gene expression, cardiomyocyte loss, impaired vascular development, and interstitial fibrosis, all worsening prognosis. 4

Reversible Myocardial Dysfunction

  • "Stunned" myocardium represents transient severe dysfunction following prolonged ischemia that persists even after blood flow restoration; intensity and duration depend on the severity and duration of the ischemic insult. 1

  • "Hibernating" myocardium is impaired function due to severely reduced coronary blood flow while myocardial cells remain intact; restoring blood flow and oxygenation can restore normal function. 1

  • Rapid restoration of oxygenation and blood flow is mandatory to reverse these pathophysiological alterations, as both mechanisms depend on the duration of myocardial damage. 1

Acute Decompensated Heart Failure: Distinct Pathophysiology

Congestion as the Central Feature

  • Acute decompensation is fundamentally a congestive syndrome where systemic venous congestion decreases venous return to right cavities (causing systemic interstitial fluid accumulation) and increases left filling pressures (causing pulmonary fluid accumulation), impairing organ perfusion. 1

  • Right ventricular dysfunction worsens decreased venous return and aggravates systemic congestion, creating a bidirectional hemodynamic crisis. 1

  • Elevated diastolic pressures play a pivotal role in both systolic heart failure (EF <50%) and diastolic heart failure (EF ≥50%), with acute decompensation associated with significant increases in estimated pulmonary artery diastolic pressure (from 17±7 to 22±7 mm Hg in diastolic HF; from 21±9 to 24±8 mm Hg in systolic HF). 5

Hemodynamic Profiles

  • Acute heart failure hemodynamics include decreased cardiac output and mixed venous oxygen saturation, together with increased left ventricular filling pressure and systemic vascular resistance. 2

  • When hypotension accompanies failure, there is markedly decreased cardiac output or inappropriate increase in systemic resistance; if acidosis is also present, cardiac output is severely decreased with elevated lactic acid. 2

  • Mismatched right- and left-sided filling pressures occur in approximately 25% of patients, impeding effective decongestion strategies. 3

Differences Between Heart Failure Phenotypes

HFrEF vs HFpEF Pathophysiology

  • Heart failure with reduced ejection fraction (HFrEF, EF <40%) typically shows end-diastolic dimension of 68±11 mm, estimated pulmonary artery diastolic pressure of 18±7 mm Hg, and diastolic distensibility index of 0.06±0.04 mm Hg/mL. 5

  • Heart failure with preserved ejection fraction (HFpEF, EF ≥50%) demonstrates EF of 58±8%, end-diastolic dimension of 50±10 mm, estimated pulmonary artery diastolic pressure of 16±9 mm Hg, and diastolic distensibility index of 0.11±0.06 mm Hg/mL. 5

  • Despite lower natriuretic peptide levels in HFpEF, both phenotypes show similar elevation of biomarkers reflecting renin-angiotensin-aldosterone system activation, oxidative stress, and collagen synthesis during acute decompensation. 6

  • HFpEF patients have more impaired vascular and renal function (higher cystatin C) but similar acute decompensated heart failure severity compared to HFrEF. 6

Acute Decompensation Triggers and Mechanisms

Ischemic Mechanisms

  • In patients with preexisting heart failure or left ventricular systolic dysfunction, relatively small ischemic events can precipitate acute decompensation due to baseline vulnerability. 1

  • In patients without prior cardiac dysfunction, large ischemic events lead to severe myocardial dysfunction that may be transient (stunned myocardium) or permanent with long-term ejection fraction changes and new wall motion abnormalities. 1

  • Patients often have underlying subclinical cardiac abnormalities related to comorbidities—especially atrial fibrillation, type 2 diabetes mellitus, or renal disease—making them vulnerable to ischemia-induced cardiac stress. 1

Gradual vs Acute Onset

  • Most hospitalizations for acute decompensated heart failure are not truly "acute" but follow a gradual rise in cardiac filling pressures over days to weeks superimposed on chronic structural heart disease. 3, 7

  • Patients presenting with elevated systolic blood pressure usually have pulmonary congestion, relatively preserved left ventricular ejection fraction, and symptoms that develop abruptly (typically elderly women). 7

  • Patients with normal systolic blood pressure presenting with systemic congestion and reduced ejection fraction are usually younger with chronic heart failure history and symptoms developing gradually over days or weeks. 7

Neurohormonal and Systemic Responses

  • Pathophysiologic processes behind remodeling reflect systemic neurohormonal activation (renin-angiotensin-aldosterone system, sympathetic nervous system), peripheral vascular effects, and localized changes affecting the cardiac substrate. 8

  • Although systemic neurohormonal blockade slows disease progression, localized ventricular remodeling still adversely affects contractile function, explaining persistent morbidity and mortality despite guideline-directed medical therapy. 8

  • Myocardial injury during acute decompensation—related to decreased coronary perfusion and/or further neurohormonal activation—contributes to short-term and post-discharge cardiac events, along with renal dysfunction (cardiorenal syndrome). 7

Critical Clinical Pitfalls

  • Do not attribute decompensation solely to volume overload; an acute precipitant (ischemia, arrhythmia, infection) is present in the majority of cases and must be identified. 3

  • Do not overlook silent myocardial ischemia in diabetic patients, who have reduced pain perception and higher incidence of acute coronary events. 3

  • Clinical evaluation of left-sided filling pressure may be misleading in acute conditions due to rapidly evolving hemodynamics; chest X-ray confirmation is essential. 1

  • High central venous pressure in acute heart failure may reflect decreased venous and right ventricular compliance even with low right ventricular filling, not just volume overload. 1

Related Questions

What is the management of acute decompensated heart failure (ADHF) with preserved ejection fraction (EF) in the elderly?
What are the criteria that define compensated chronic heart failure?
What diagnostic workup is indicated for a patient presenting with dyspnea and bilateral peripheral edema?
What are the typical ECG (electrocardiogram) changes and management strategies for patients with stage B heart failure, particularly those with reduced ejection fraction?
What is the best management plan for an elderly male patient with acute decompensated heart failure (ADHF) and type 2 heart failure with preserved ejection fraction (HFpEF), community-acquired pneumonia (CAP), mild chronic obstructive pulmonary disease (COPD) exacerbation, mild traumatic brain injury (TBI), and newly diagnosed hypertension (HTN)?
For a 40‑70‑year‑old adult with CEAP (Clinical‑Etiologic‑Anatomic‑Pathophysiologic) class C2‑C3 varicose veins, duplex ultrasound showing ≥500 ms reflux at the saphenofemoral junction and a great saphenous vein (GSV) diameter ≥4.5 mm, what are the indications and step‑by‑step operative and postoperative management for a Trendelenburg (great‑saphenous‑vein ligation) surgery?
What evaluation and management should I provide for an 85‑year‑old woman with new‑onset uncontrolled bowel movements, beyond stool testing for infection, to address possible fecal incontinence?
What are the etiologies of hepatic steatosis?
What are the recommended age‑appropriate preventative screening tests and intervals for a healthy adult without known disease?
Are Ditropan (oxybutynin) and Detrol (tolterodine) the same medication?
What is the recommended treatment for an acute pseudogout flare in an elderly, frail patient with renal impairment, peptic ulcer disease, or heart failure, and how should recurrent attacks be prophylactically managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.